RT Journal Article SR Electronic T1 Traditional Chinese Medicine Xihuang Wan Inhibited Lewis Lung Carcinoma in a Syngeneic Model, Equivalent to Cytotoxic Chemotherapy, by Altering Multiple Signaling Pathways JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 2005 OP 2014 DO 10.21873/invivo.12469 VO 35 IS 4 A1 ZHIYING ZHANG A1 JIANFENG WANG A1 HUA DUAN A1 DIANNA LIU A1 XIANGNAN ZHOU A1 XIMING LIN A1 HAOYUE PANG A1 MANQIANG SUN A1 TIAN ZHOU A1 ROBERT M. HOFFMAN A1 KAIWEN HU YR 2021 UL http://iv.iiarjournals.org/content/35/4/2005.abstract AB Background/Aim: Xihuang Wan (XHW), a traditional Chinese medicine (TCM), has been used in China for a variety of cancers including lung cancer. The present study evaluated the efficacy of XHW on a Lewis lung mouse model and explored the potential mechanism via transcriptomics. Materials and Methods: The mice were randomized into 6 groups: 1) untreated control (n=10); 2) low-dose XHW; 3) medium-dose XHW; 4) high-dose XHW; 5) cisplatin; and 6) untreated blank (n=4). Lewis lung carcinoma (LLC) cells were injected subcutaneously except for the 4 mice in the blank group. The body weight and tumor length and width were measured every 3 days. RNA-sequencing was performed on tumors in the high-dose XHW group and the control group. Results: XHW inhibited the growth of LLC in a syngeneic mouse model, without toxicity, with equivalent efficacy to cisplatin. RNA-sequencing demonstrated that many signaling pathways were involved in XHW-mediated inhibition of LLC, including tumor necrosis factor, estrogen, cyclic guanosine 3’, 5’-monophosphate-protein kinase G, apelin and the peroxisome proliferator-activated receptor signaling pathways. Conclusion: XHW inhibited LLC carcinoma through different pathways and shows clinical promise for patients who cannot tolerate platinum-based drugs.